Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab in Refractory Ewing's Sarcoma
NCT05968768Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in Ewing sarcoma. Started Oct 2023; status: recruiting.
02
Drugs
naxitamab
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT05968768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968768.